Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

274

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Diseases
Cardiovascular Abnormalities
Calcifications, Vascular
Endstage Renal Disease
ESRD
Coronary Artery Calcification

Interventions

DRUG: SNF472
DRUG: Placebo

Sponsor

Sanifit Therapeutics S. A.

Collaborators

[object Object]